Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genmab
Pharma
Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia
In two deals potentially worth $2 billion each, Novo gained a "triple G" candidate from United Labs as Merck bought a CV asset from Hengrui.
Angus Liu
Mar 28, 2025 9:28am
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
EU signs off on Regeneron's T-cell engager for 2 blood cancers
Aug 26, 2024 10:35am
Genmab shuffles C-Suite as portfolio grows
Aug 19, 2024 10:08am
AbbVie's Epkinly follows Roche's Lunsumio into FL
Jun 27, 2024 10:21am
Genmab to expand in New Jersey in bid to boost Epkinly rollout
Mar 28, 2024 4:29pm
